A Phase 1, Double Blind, Third-Party Open, Randomized, Placebo Controlled, Single And Multiple Dose, Parallel Group Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of PF-06687234 In Healthy Subjects

Trial Profile

A Phase 1, Double Blind, Third-Party Open, Randomized, Placebo Controlled, Single And Multiple Dose, Parallel Group Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of PF-06687234 In Healthy Subjects

Discontinued
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2016

At a glance

  • Drugs F8 IL10 (Primary) ; F8 IL10 (Primary)
  • Indications Inflammation; Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 04 Nov 2016 Status changed from recruiting to discontinued.
    • 25 Jul 2016 Planned End Date changed from 1 Nov 2017 to 1 Aug 2017.
    • 25 Jul 2016 Planned primary completion date changed from 1 Nov 2017 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top